{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,10,17]],"date-time":"2024-10-17T04:32:03Z","timestamp":1729139523289,"version":"3.27.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2024,8,14]],"date-time":"2024-08-14T00:00:00Z","timestamp":1723593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,8,14]],"date-time":"2024-08-14T00:00:00Z","timestamp":1723593600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Z Rheumatol"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1007\/s00393-024-01556-1","type":"journal-article","created":{"date-parts":[[2024,8,14]],"date-time":"2024-08-14T17:01:50Z","timestamp":1723654910000},"page":"634-640","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Head-to-Head-Studien bei Psoriasis und Psoriasisarthritis","Head-to-head studies on psoriasis and psoriatic arthritis"],"prefix":"10.1007","volume":"83","author":[{"given":"Fredrik N.","family":"Albach","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michaela","family":"K\u00f6hm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Simon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,8,14]]},"reference":[{"key":"1556_CR1","doi-asserted-by":"publisher","first-page":"e12946","DOI":"10.1111\/sji.12946","volume":"92","author":"LL Ten Bergen","year":"2020","unstructured":"Ten Bergen\u00a0LL, Petrovic\u00a0A, Krogh Aarebrot\u00a0A et\u00a0al (2020) The TNF\/IL-23\/IL-17 axis-Head-to-head trials comparing different biologics in psoriasis treatment. Scand J Immunol 92:e12946. https:\/\/doi.org\/10.1111\/sji.12946","journal-title":"Scand J Immunol"},{"key":"1556_CR2","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1111\/bjd.14867","volume":"176","author":"AC de Vries","year":"2017","unstructured":"de Vries\u00a0AC, Thio\u00a0HB, de Kort\u00a0WJ et\u00a0al (2017) A\u00a0prospective randomized controlled trial comparing infliximab and etanercept in patients with moderate-to-severe chronic plaque-type psoriasis: the Psoriasis Infliximab vs. Etanercept Comparison Evaluation (PIECE) study. Br J Dermatol 176:624\u2013633. https:\/\/doi.org\/10.1111\/bjd.14867","journal-title":"Br J Dermatol"},{"key":"1556_CR3","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1007\/s00393-023-01409-3","volume":"83","author":"FN Albach","year":"2024","unstructured":"Albach\u00a0FN, Burmester\u00a0GR, Mucke\u00a0J (2024) Therapeutic antibodies in rheumatology. Z\u00a0Rheumatol 83:98\u2013104. https:\/\/doi.org\/10.1007\/s00393-023-01409-3","journal-title":"Z Rheumatol"},{"key":"1556_CR4","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1056\/NEJMoa0810652","volume":"362","author":"CE Griffiths","year":"2010","unstructured":"Griffiths\u00a0CE, Strober\u00a0BE, van de Kerkhof\u00a0P et\u00a0al (2010) Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N\u00a0Engl J Med 362:118\u2013128. https:\/\/doi.org\/10.1056\/NEJMoa0810652","journal-title":"N Engl J Med"},{"key":"1556_CR5","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1056\/NEJMoa1314258","volume":"371","author":"RG Langley","year":"2014","unstructured":"Langley\u00a0RG, Elewski\u00a0BE, Lebwohl\u00a0M et\u00a0al (2014) Secukinumab in plaque psoriasis\u2013results of two phase\u00a03\u00a0trials. N\u00a0Engl J Med 371:326\u2013338. https:\/\/doi.org\/10.1056\/NEJMoa1314258","journal-title":"N Engl J Med"},{"key":"1556_CR6","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1056\/NEJMc1610828","volume":"375","author":"KB Gordon","year":"2016","unstructured":"Gordon\u00a0KB, Colombel\u00a0JF, Hardin\u00a0DS (2016) Phase\u00a03 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis. N\u00a0Engl J Med 375:2102. https:\/\/doi.org\/10.1056\/NEJMc1610828","journal-title":"N Engl J Med"},{"key":"1556_CR7","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/S0140-6736(21)00125-2","volume":"397","author":"K Reich","year":"2021","unstructured":"Reich\u00a0K, Papp\u00a0KA, Blauvelt\u00a0A et\u00a0al (2021) Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a\u00a052-week, multicentre, double-blind, active comparator and placebo controlled phase\u00a03\u00a0trial. Lancet 397:487\u2013498. https:\/\/doi.org\/10.1016\/S0140-6736(21)00125-2","journal-title":"Lancet"},{"key":"1556_CR8","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1111\/bjd.19509","volume":"184","author":"A Blauvelt","year":"2021","unstructured":"Blauvelt\u00a0A, Leonardi\u00a0C, Elewski\u00a0B et\u00a0al (2021) A\u00a0head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 24-week efficacy and safety results from a\u00a0randomized, double-blinded trial. Br J Dermatol 184:1047\u20131058. https:\/\/doi.org\/10.1111\/bjd.19509","journal-title":"Br J Dermatol"},{"key":"1556_CR9","doi-asserted-by":"publisher","first-page":"CD011535","DOI":"10.1002\/14651858.CD011535.pub6","volume":"7","author":"E Sbidian","year":"2023","unstructured":"Sbidian\u00a0E, Chaimani\u00a0A, Guelimi\u00a0R et\u00a0al (2023) Systemic pharmacological treatments for chronic plaque psoriasis: a\u00a0network meta-analysis. Cochrane Database Syst Rev 7:CD11535. https:\/\/doi.org\/10.1002\/14651858.CD011535.pub6","journal-title":"Cochrane Database Syst Rev"},{"key":"1556_CR10","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1111\/ddg.14507_g","volume":"19","author":"A Nast","year":"2021","unstructured":"Nast\u00a0A, Altenburg\u00a0A, Augustin\u00a0M et\u00a0al (2021) Deutsche S3-Leitlinie zur Therapie der Psoriasis vulgaris, adaptiert von EuroGuiDerm \u2013 Teil\u00a02: Therapiemonitoring, besondere klinische Situationen und Komorbidit\u00e4t. J\u00a0Dtsch Dermatol Ges 19:1092\u20131117. https:\/\/doi.org\/10.1111\/ddg.14507_g","journal-title":"J Dtsch Dermatol Ges"},{"key":"1556_CR11","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1002\/art.40851","volume":"71","author":"PJ Mease","year":"2019","unstructured":"Mease\u00a0PJ, Gladman\u00a0DD, Collier\u00a0DH et\u00a0al (2019) Etanercept and Methotrexate as Monotherapy or in Combination for Psoriatic Arthritis: Primary Results From a\u00a0Randomized, Controlled Phase\u00a0III Trial. Arthritis Rheumatol 71:1112\u20131124. https:\/\/doi.org\/10.1002\/art.40851","journal-title":"Arthritis Rheumatol"},{"key":"1556_CR12","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1093\/rheumatology\/kes001","volume":"51","author":"GH Kingsley","year":"2012","unstructured":"Kingsley\u00a0GH, Kowalczyk\u00a0A, Taylor\u00a0H et\u00a0al (2012) A\u00a0randomized placebo-controlled trial of methotrexate in psoriatic arthritis. Rheumatology 51:1368\u20131377. https:\/\/doi.org\/10.1093\/rheumatology\/kes001","journal-title":"Rheumatology"},{"key":"1556_CR13","doi-asserted-by":"publisher","first-page":"e14","DOI":"10.1016\/S2665-9913(22)00329-0","volume":"5","author":"M Koehm","year":"2023","unstructured":"Koehm\u00a0M, Rossmanith\u00a0T, Foldenauer\u00a0AC et\u00a0al (2023) Methotrexate plus ustekinumab versus ustekinumab monotherapy in patients with active psoriatic arthritis (MUST): a\u00a0randomised, multicentre, placebo-controlled, phase\u00a03b, non-inferiority trial. Lancet Rheumatol 5:e14\u2013e23. https:\/\/doi.org\/10.1016\/S2665-9913(22)00329-0","journal-title":"Lancet Rheumatol"},{"key":"1556_CR14","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1136\/annrheumdis-2019-215386","volume":"79","author":"PJ Mease","year":"2020","unstructured":"Mease\u00a0PJ, Smolen\u00a0JS, Behrens\u00a0F et\u00a0al (2020) A\u00a0head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-na\u00efve patients with active psoriatic arthritis: 24-week results of a\u00a0randomised, open-label, blinded-assessor trial. Ann Rheum Dis 79:123\u2013131. https:\/\/doi.org\/10.1136\/annrheumdis-2019-215386","journal-title":"Ann Rheum Dis"},{"key":"1556_CR15","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1016\/S0140-6736(20)30564-X","volume":"395","author":"IB McInnes","year":"2020","unstructured":"McInnes\u00a0IB, Behrens\u00a0F, Mease\u00a0PJ et\u00a0al (2020) Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a\u00a0double-blind, parallel-group, randomised, active-controlled, phase\u00a03b\u00a0trial. Lancet 395:1496\u20131505. https:\/\/doi.org\/10.1016\/S0140-6736(20)30564-X","journal-title":"Lancet"},{"key":"1556_CR16","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1056\/NEJMoa2022516","volume":"384","author":"IB McInnes","year":"2021","unstructured":"McInnes\u00a0IB, Anderson\u00a0JK, Magrey\u00a0M et\u00a0al (2021) Trial of Upadacitinib and Adalimumab for Psoriatic Arthritis. N\u00a0Engl J Med 384:1227\u20131239. https:\/\/doi.org\/10.1056\/NEJMoa2022516","journal-title":"N Engl J Med"},{"key":"1556_CR17","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/j.semarthrit.2018.05.011","volume":"48","author":"EG Araujo","year":"2019","unstructured":"Araujo\u00a0EG, Englbrecht\u00a0M, Hoepken\u00a0S et\u00a0al (2019) Effects of ustekinumab versus tumor necrosis factor inhibition on enthesitis: Results from the enthesial clearance in psoriatic arthritis (ECLIPSA) study. Semin Arthritis Rheum 48:632\u2013637. https:\/\/doi.org\/10.1016\/j.semarthrit.2018.05.011","journal-title":"Semin Arthritis Rheum"},{"key":"1556_CR18","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2019-001117","author":"A Ruyssen-Witrand","year":"2020","unstructured":"Ruyssen-Witrand\u00a0A, Perry\u00a0R, Watkins\u00a0C et\u00a0al (2020) Efficacy and safety of biologics in psoriatic arthritis: a\u00a0systematic literature review and network meta-analysis. RMD Open. https:\/\/doi.org\/10.1136\/rmdopen-2019-001117","journal-title":"RMD Open"},{"key":"1556_CR19","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2023-003423","author":"PJ Mease","year":"2024","unstructured":"Mease\u00a0PJ, Reddy\u00a0S, Ross\u00a0S et\u00a0al (2024) Evaluating the efficacy of biologics with and without methotrexate in the treatment of psoriatic arthritis: a\u00a0network meta-analysis. Rmd Open. https:\/\/doi.org\/10.1136\/rmdopen-2023-003423","journal-title":"Rmd Open"},{"key":"1556_CR20","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2024-225531","author":"L Gossec","year":"2024","unstructured":"Gossec\u00a0L, Kerschbaumer\u00a0A, Ferreira\u00a0RJO et\u00a0al (2024) EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update. Ann Rheum Dis. https:\/\/doi.org\/10.1136\/ard-2024-225531","journal-title":"Ann Rheum Dis"},{"key":"1556_CR21","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/s41584-022-00798-0","volume":"18","author":"LC Coates","year":"2022","unstructured":"Coates\u00a0LC, Soriano\u00a0ER, Corp\u00a0N et\u00a0al (2022) Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021. Nat Rev Rheumatol 18:465\u2013479. https:\/\/doi.org\/10.1038\/s41584-022-00798-0","journal-title":"Nat Rev Rheumatol"}],"container-title":["Zeitschrift f\u00fcr Rheumatologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-024-01556-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00393-024-01556-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-024-01556-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T21:02:05Z","timestamp":1729112525000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00393-024-01556-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,14]]},"references-count":21,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["1556"],"URL":"https:\/\/doi.org\/10.1007\/s00393-024-01556-1","relation":{},"ISSN":["0340-1855","1435-1250"],"issn-type":[{"type":"print","value":"0340-1855"},{"type":"electronic","value":"1435-1250"}],"subject":[],"published":{"date-parts":[[2024,8,14]]},"assertion":[{"value":"27 July 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"F.N.\u00a0Albach gibt an, dass kein Interessenkonflikt besteht. M.\u00a0K\u00f6hm hat Honorare von folgenden Firmen erhalten: AbbVie Deutschland GmbH & Co. KG, Amgen GmbH, Janssen-Cilag GmbH, Lilly Deutschland GmbH, Novartis Pharma GmbH, GlaxoSmithKline GmbH & Co. KG, Bristol Meyer Squibb. D.\u00a0Simon hat Honorare von folgenden Firmen erhalten: AbbVie Deutschland GmbH & Co. KG, Amgen GmbH, Galapagos NV, Janssen-Cilag GmbH, Lilly Deutschland GmbH, Novartis Pharma GmbH, medac Gesellschaft f\u00fcr klinische Spezialpr\u00e4parate mbH, GlaxoSmithKline GmbH & Co. KG.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}